BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Condition: Ovarian Neoplasms; Peritoneal Neoplasms
MeSH terms: Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
Intervention: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min; BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Intervention description: BIBF1120 twice daily along with standard therapy of PLD + carboplatin; BIBF1120 twice daily along with standard therapy of PLD + carboplatin; BIBF1120 twice daily along with standard therapy of PLD + carboplatin
Intervention MeSH terms: Carboplatin; Nintedanib
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 19.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to
      treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in
      patients with advanced, platinum sensitive relapsed ovarian cancer, fallopian tube carcinoma
      or primary peritoneal cancer.
    

Eligibility criteria:

        Inclusion criteria:

          1. Female patients, age 18 years or older, with a first, second or third relapse of
             histologically (on initial diagnosis) confirmed epithelial ovarian cancer, fallopian
             tube carcinoma or primary peritoneal cancer

          2. Up to three lines of prior chemo (chemotherapy before and after interval surgery to be
             counted as one line therapy), with treatment free interval of > 6 months (= time
             between last administration of prior anti-cancer treatment, including chemotherapy,
             hormonal therapy, or radiation therapy, and diagnosis of progressive disease)

          3. Platinum based chemo in immediately preceding line

          4. Eligibility for treatment with i.v. chemotherapy regimen of carboplatin AUC 5 and PLD
             30 mg/m2 every 4 weeks

          5. Life expectancy of at least 3 months

          6. Written informed consent that is consistent with International Conference of
             Harmonisation (ICH)-Good Clinical Practice (GCP) guidelines

          7. Eastern Cooperative Oncology Group (ECOG) performance score 0 or1

          8. Prior treatment with angiogenesis inhibitor (bevacizumab, TKI inhibiting VEGFR-2) is
             allowed provided treatment with bevacizumab has been discontinued = 28 days prior to
             start of therapy and treatment with the TKI has been discontinued = 3 months prior to
             start of therapy, provided anti-angiogenic therapy was added to only one of the
             preceding lines of therapy

        Exclusion criteria:

          1. Prior chemotherapy with doxorubicin (any formulation, liposomal or non-liposomal
             doxorubicin).

          2. Any contraindications for therapy with PLD or carboplatin, e.g. a history of
             hypersensitivity reactions to platinum-containing compounds and their excipients.

          3. Hypersensitivity to active substance or to any of the excipients of BIBF 1120.

          4. Treatment with other investigational drugs or participation in another clinical trial
             testing a drug within the past four weeks before start of therapy or concomitantly
             with this trial (exception: for previous treatment with angiogenesis inhibitors, cf.
             inclusion criterion #8).

          5. Laboratory values indicating an increased risk for adverse events.

          6. Major surgery within 4 weeks prior to start of study treatment.

          7. Patients for whom surgery is planned, e.g. interval debulking surgery.

          8. Clinically relevant non-healing wound, ulcer (intestinal tract, skin) or bone
             fracture.

          9. Clinical symptoms or signs of gastrointestinal obstruction that require parenteral
             nutrition or hydration.

         10. Gastrointestinal disorders or abnormalities that would interfere with absorption of
             the study drug.

         11. History of clinical symptoms of brain metastases.

         12. Prior thrombosis or thromboembolic event in the presence of an inherited coagulopathy.

         13. History of a cerebral vascular accident, transient ischemic attack or subarachnoid
             haemorrhage within the past 6 months.

         14. Known inherited or acquired bleeding disorder.

         15. Significant cardiovascular diseases.

         16. Serious infections in particular if requiring systemic antibiotic (antimicrobial,
             antifungal) or antiviral therapy.

         17. Other malignancy diagnosed within the past 5 years.

         18. Known serious illness or concomitant non-oncological disease.

         19. Patients unable to comply with the protocol.

         20. Patients with preserved reproductive capacity who are sexually active and unwilling to
             use a medically acceptable method of contraception.

         21. Pregnancy or breast feeding.